InMed Pharmaceuticals News

Press Releases

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

January 18, 2024

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

January 16, 2024

InMed Announces Results of 2023 Annual General Meeting

December 19, 2023

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

November 29, 2023

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

November 14, 2023

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

November 2, 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

October 26, 2023

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

October 24, 2023

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

October 24, 2023

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

September 29, 2023

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

September 22, 2023

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 7, 2023

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

July 21, 2023

InMed Provides Update on BayMedica Rare Cannabinoid Business

July 20, 2023

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

June 22, 2023

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

June 1, 2023

InMed to Participate in Upcoming Virtual Investor Events

May 24, 2023

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

May 18, 2023

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 15, 2023

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

March 28, 2023

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

InMed Provides Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

InMed to Participate in Upcoming Virtual Investor Events

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals